Halozyme Therapeutics (NASDAQ:HALO) Price Target Raised to $75.00 at Wells Fargo & Company

Halozyme Therapeutics (NASDAQ:HALO) had its price target increased by equities research analysts at Wells Fargo & Company from $65.00 to $75.00 in a research report issued on Thursday,Benzinga reports. The firm currently has an “equal weight” rating on the biopharmaceutical company’s stock. Wells Fargo & Company‘s price target indicates a potential upside of 4.47% from the company’s current price.

A number of other research analysts have also recently weighed in on the company. Citigroup reiterated a “market outperform” rating on shares of Halozyme Therapeutics in a report on Tuesday, November 4th. Benchmark restated a “buy” rating on shares of Halozyme Therapeutics in a report on Tuesday, February 3rd. TD Cowen reiterated a “buy” rating on shares of Halozyme Therapeutics in a research note on Wednesday. JPMorgan Chase & Co. raised their target price on shares of Halozyme Therapeutics from $63.00 to $65.00 and gave the company a “neutral” rating in a research note on Monday, October 27th. Finally, Weiss Ratings upgraded Halozyme Therapeutics from a “hold (c+)” rating to a “buy (b-)” rating in a report on Tuesday, February 10th. Seven equities research analysts have rated the stock with a Buy rating, four have assigned a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $78.56.

Halozyme Therapeutics Price Performance

Halozyme Therapeutics stock opened at $71.79 on Thursday. The company has a quick ratio of 1.37, a current ratio of 1.59 and a debt-to-equity ratio of 1.59. The firm’s 50-day simple moving average is $71.77 and its 200 day simple moving average is $70.27. Halozyme Therapeutics has a 52 week low of $47.50 and a 52 week high of $82.22. The firm has a market capitalization of $8.44 billion, a PE ratio of 28.74, a P/E/G ratio of 0.33 and a beta of 0.97.

Halozyme Therapeutics (NASDAQ:HALO) last issued its quarterly earnings results on Tuesday, February 17th. The biopharmaceutical company reported ($0.24) EPS for the quarter, missing analysts’ consensus estimates of $1.92 by ($2.16). Halozyme Therapeutics had a return on equity of 105.87% and a net margin of 22.69%.The firm had revenue of $451.77 million for the quarter, compared to analysts’ expectations of $446.13 million. During the same quarter last year, the firm earned $1.26 earnings per share. The business’s quarterly revenue was up 51.6% compared to the same quarter last year. On average, equities research analysts predict that Halozyme Therapeutics will post 4.73 EPS for the current fiscal year.

Insider Activity at Halozyme Therapeutics

In other Halozyme Therapeutics news, CEO Helen Torley sold 20,000 shares of the firm’s stock in a transaction dated Tuesday, February 3rd. The shares were sold at an average price of $76.12, for a total transaction of $1,522,400.00. Following the completion of the transaction, the chief executive officer owned 708,719 shares in the company, valued at $53,947,690.28. This trade represents a 2.74% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, Director Bernadette Connaughton sold 2,000 shares of the company’s stock in a transaction that occurred on Monday, January 5th. The shares were sold at an average price of $70.25, for a total transaction of $140,500.00. Following the completion of the transaction, the director owned 40,123 shares of the company’s stock, valued at $2,818,640.75. This trade represents a 4.75% decrease in their position. The SEC filing for this sale provides additional information. Insiders sold 49,398 shares of company stock valued at $3,650,592 over the last quarter. Insiders own 2.40% of the company’s stock.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently bought and sold shares of the business. DLD Asset Management LP grew its position in shares of Halozyme Therapeutics by 20.0% in the third quarter. DLD Asset Management LP now owns 30,000,000 shares of the biopharmaceutical company’s stock valued at $2,200,200,000 after purchasing an additional 5,000,000 shares in the last quarter. Arrowstreet Capital Limited Partnership raised its stake in Halozyme Therapeutics by 29.5% in the third quarter. Arrowstreet Capital Limited Partnership now owns 3,290,665 shares of the biopharmaceutical company’s stock worth $241,337,000 after buying an additional 749,484 shares in the last quarter. Dimensional Fund Advisors LP boosted its position in Halozyme Therapeutics by 1.2% during the fourth quarter. Dimensional Fund Advisors LP now owns 2,104,157 shares of the biopharmaceutical company’s stock worth $141,613,000 after purchasing an additional 25,731 shares in the last quarter. Norges Bank acquired a new position in shares of Halozyme Therapeutics during the fourth quarter valued at approximately $128,201,000. Finally, William Blair Investment Management LLC purchased a new stake in shares of Halozyme Therapeutics during the fourth quarter worth approximately $124,031,000. Institutional investors own 97.79% of the company’s stock.

More Halozyme Therapeutics News

Here are the key news stories impacting Halozyme Therapeutics this week:

• Positive Sentiment: Reported record full‑year 2025 revenue of $1.397B, raised forward financial targets and reiterated strong 2026 guidance (2026 revenue $1.71–$1.81B; adjusted EBITDA $1.125–$1.205B; non‑GAAP EPS $7.75–$8.25). Management also closed acquisitions (Hypercon technologies) that it says expand product/technology optionality — a clear signal management expects much stronger profitability in 2026. HALOZYME REPORTS FULL YEAR 2025 RECORD REVENUE
• Positive Sentiment: Q4 total revenue rose ~52% y/y to $451.8M, driven by higher royalty revenue and product sales — revenue slightly beat consensus, showing underlying ENHANZE/royalty momentum that should feed 2026 top‑line targets. Halozyme’s Q4 Earnings Miss, Higher Royalties Drive Y/Y Revenues
• Neutral Sentiment: Earnings call and slide deck emphasize strong recurring royalty streams and a pathway to much higher adjusted EBITDA in 2026; investors should watch cadence of royalty receipts and margin recovery called out by management. Q4 2025 Earnings Call Transcript
• Neutral Sentiment: Some analysts and commentators are debating whether current valuation already prices in the 2026 profitability swing; valuation conversations may limit upside until quarterly cash/earnings execution confirms guidance. Is HALO Stock Price Out Of Step With Recent Valuation Signals
• Negative Sentiment: Q4 swung to a surprise GAAP loss (reported EPS -$0.24 vs. Street e.g. ~$1.92), driven by an acquisition-related charge and higher operating costs — the large EPS miss triggered an immediate negative market reaction. Halozyme Stock Declines on Swing to Surprise 4Q Loss
• Negative Sentiment: Q4 operating and net losses widened; liabilities increased year‑over‑year and recent insider sales (reported in market summaries) may concern some holders — watch cash, debt metrics and any further one‑time charges in coming reports. Halozyme Stock Falls on Q4 2025 Earnings

Halozyme Therapeutics Company Profile

Halozyme Therapeutics, Inc is a biopharmaceutical company headquartered in San Diego, California, that specializes in the development and commercialization of novel drug-delivery technologies. Founded in 1998, Halozyme focuses on enabling subcutaneous administration of biologic therapies through its proprietary platforms. The company’s core mission is to improve patient access and convenience while maintaining efficacy and safety profiles comparable to or better than traditional routes of administration.

The company’s flagship technology, ENHANZE®, is based on recombinant human hyaluronidase PH20 (rHuPH20), an enzyme that transiently degrades hyaluronan in the extracellular matrix.